A lab operated by controversial blood testing startup Theranos poses "immediate jeopardy to patient health and safety," the Centers for Medicare & Medicaid Services said in a letter released Wednesday.
CMS detailed five different conditions the California lab did not meet, including those relating to its director, technical supervisor and personnel.
The letter, dated Monday, gives the company 10 days to correct the noted deficiencies. It also notes that the company can face daily fines for noncompliance and/or the loss of its approval to receive Medicare payments.
Theranos has been under fire for months after a series of reports in the Wall Street Journal raised questions about the quality of its testing technology.